veliparib (ABT-888)

News alerts, weekly reports and conference planners

Company:

AbbVie

Drug class:

PARP inhibitor

Related drugs:

‹

›

BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
BRCA1 mutation	Hormone Receptor Positive Breast Cancer	BRCA1 mutation	Hormone Receptor Positive Breast Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
BRCA2 mutation	Hormone Receptor Positive Breast Cancer	BRCA2 mutation	Hormone Receptor Positive Breast Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
HRD	Ovarian Cancer	HRD	Ovarian Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
MUC16 overexpression	Ovarian Cancer	MUC16 overexpression	Ovarian Cancer	ABT-888 Resistant: B - Late Trials ABT-888 Resistant : B	ABT-888 Resistant: B - Late Trials ABT-888 Resistant : B
TMB-H	Ovarian Cancer	TMB-H	Ovarian Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
BRCA2 mutation	Pancreatic Cancer	BRCA2 mutation	Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2
PALB2 mutation	Pancreatic Cancer	PALB2 mutation	Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2
BRCA1 mutation	Pancreatic Cancer	BRCA1 mutation	Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2
BRCA1 mutation	Solid Tumor	BRCA1 mutation	Solid Tumor	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2
CCND1-H	Breast Cancer	CCND1-H	Breast Cancer	ABT-888 Resistant: C3 – Early Trials ABT-888 Resistant : C3	ABT-888 Resistant: C3 – Early Trials ABT-888 Resistant : C3
CCND1 overexpression	Breast Cancer	CCND1 overexpression	Breast Cancer	ABT-888 Resistant: C3 – Early Trials ABT-888 Resistant : C3	ABT-888 Resistant: C3 – Early Trials ABT-888 Resistant : C3
BRIP1 mutation	Pancreatic Cancer	BRIP1 mutation	Pancreatic Cancer	nivolumab + ABT-888 Sensitive: C3 – Early Trials nivolumab + ABT-888 Sensitive : C3	nivolumab + ABT-888 Sensitive: C3 – Early Trials nivolumab + ABT-888 Sensitive : C3
SLFN11 expression	Small Cell Lung Cancer	SLFN11 expression	Small Cell Lung Cancer	ABT-888 Sensitive: C3 – Early Trials ABT-888 Sensitive : C3	ABT-888 Sensitive: C3 – Early Trials ABT-888 Sensitive : C3
HOXA9 methylation	Ovarian Cancer	HOXA9 methylation	Ovarian Cancer	ABT-888 Resistant: C3 – Early Trials ABT-888 Resistant : C3	ABT-888 Resistant: C3 – Early Trials ABT-888 Resistant : C3
DDR	Non Small Cell Lung Cancer	DDR	Non Small Cell Lung Cancer	ABT-888 Sensitive: C3 – Early Trials ABT-888 Sensitive : C3	ABT-888 Sensitive: C3 – Early Trials ABT-888 Sensitive : C3
SLFN11 expression	Small Cell Lung Cancer	SLFN11 expression	Small Cell Lung Cancer	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3
CHEK2 mutation	Tongue Carcinoma	CHEK2 mutation	Tongue Carcinoma	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4
ATM mutation	Breast Cancer	ATM mutation	Breast Cancer	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4
BRIP1 L680fs*9	Pancreatic Cancer	BRIP1 L680fs*9	Pancreatic Cancer	nivolumab + ABT-888 Sensitive: C4 – Case Studies nivolumab + ABT-888 Sensitive : C4	nivolumab + ABT-888 Sensitive: C4 – Case Studies nivolumab + ABT-888 Sensitive : C4

veliparib (ABT-888)

Associations
(35)

Associations
(35)

veliparib (ABT-888)

Associations(35)

Associations(35)

Associations
(35)

Associations
(35)